<DOC>
	<DOCNO>NCT00886457</DOCNO>
	<brief_summary>The purpose study assess toxicity 1-hr infusion 5-aza-2'-deoxycytidine ( decitabine ) x 10 day ( M-F ) plus escalate dos weekly subcutaneous PEG-interferon-α ( PEG-Intron ) patient metastatic cancer identify maximum tolerate dose PEG-Intron combination . The pre- post-treatment sample evaluate identify change molecular correlate .</brief_summary>
	<brief_title>5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B : A Phase I Study With Molecular Correlates</brief_title>
	<detailed_description />
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1 . Patient must biopsy proven cancer , metastatic unresectable , ( opinion investigator ) , curative effective treatment exists . 2 . Patient must biopsy accessible tumor must indicate willingness undergo biopsy tumor normal skin day 1 , 15 29 . 3 . Patient must measurable disease RECIST criterion scan perform within 28 day study enrollment . 4 . Patient may untreated brain metastasis . Patients previously treat brain metastasis must longer receive steroid therapy treatment brain metastasis . 5 . Patient must Zubrod performance status 0 2 . 6 . Prior surgery , radiotherapy chemotherapy allow . The patient must receive chemotherapy , radiotherapy , surgery , biologic therapy investigational drug reason within 28 day prior registration . Concomitant treatment anticancer agent radiotherapy , include investigational agent course study treatment allow . 7 . Patients extensive pelvic irradiation prolong nucleoside analogue pretreatment exclude due increase risk hematologic toxicity . 8 . Patient must adequate liver function define serum bilirubin ≤ 1.5 x institutional upper limit normal ( IULN ) , SGOT SGPT ≤ 2.5 x institutional upper limit normal ( ≤ 5 x institutional upper limit normal hepatic metastasis present ) obtain within 14 day prior registration . 9 . Patient must adequate renal function define serum creatinine ≤ 1.5 x institutional upper limit normal , well calculate measure creatinine clearance ( CrCl ) ≥ 50 ml/min . 10 . Patient must ANC &gt; 1,500/μl , platelet count &gt; 100,000/μl hemoglobin &gt; 9 gm/dl ( may achieve transfusion need ) obtain within 14 day prior registration . 11 . All patient must inform investigational nature study must provide write acknowledgment inform consent accordance institutional federal guideline . 12 . Both men woman race ethnic group eligible trial . 13 . Patients must ≥ 18 year age . 1 . Class 3/4 cardiac problem define New York Heart Association Criteria ( e.g. , congestive heart failure , myocardial infarction within 2 month study ) . 2 . Severe and/or uncontrolled concurrent medical disease ( e.g. , uncontrolled diabetes , uncontrolled chronic renal liver disease , active uncontrolled infection , e.g. , HIV ) . 3 . Patient must pregnant nursing mother PEGIntron decitabine may harmful develop fetus newborn . Women/men reproductive potential must agree use effective contraceptive method . Women reproductive potential must negative serum pregnancy test within 7 day prior registration . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug . 4 . Medical psychological condition , opinion investigator , make patient unable tolerate complete treatment , grant reliable inform consent eligible study . 5 . No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I , II , III cancer patient currently complete remission , cancer patient diseasefree 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Biopsy proven cancer , metastatic unresectable</keyword>
</DOC>